Histology and sensitivity to anticancer drugs of two human non-small cell lung carcinomas implanted in the pleural cavity of nude mice

Clinical Cancer Research

Volumn 6, Issue 1, 2000, Pages 297-304

  Kraus Berthier, Laurence ^a   Jan, Michel ^a   Guilbaud, Nicolas ^a   Naze, Monique ^a   Pierré, Alain ^a   Atassi, Ghanem ^a  

^a INSTITUT DE RECHERCHES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IRINOTECAN; N (2 DIMETHYLAMINOETHYL) 9 HYDROXY 5,6 DIMETHYL 6H PYRIDO[4,3 B]CARBAZOLE 1 CARBOXAMIDE; NAVELBINE; OLIVACINE; PACLITAXEL; TOPOTECAN; VINBLASTINE; VINBLASTINE SULFATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GRAFT; CANCER RESISTANCE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HISTOPATHOLOGY; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; NUDE MOUSE; PLEURA CAVITY; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; DOXORUBICIN; ELLIPTICINES; ETOPOSIDE; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MICE; MICE, NUDE; NEOPLASM METASTASIS; PACLITAXEL; PLEURAL NEOPLASMS; TOPOTECAN; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; VINBLASTINE;

EID: 0033971812     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Sorensen, J. B., Clerici, M., and Hansen, H. H. Single-agent chemotherapy for advanced adenocarcinoma of the lung. Cancer Chemother. Pharmacol., 21: 89-102, 1988.
2. Dancey, J., and Le Chevalier, T. Non-small cell lung cancer: an overview of current management. Eur. J. Cancer, 33 (Suppl. 1): S2-S7, 1997.
3. McLemore, T. L., Eggleston, J. C., Shoemaker, R. H., Abbott, B. J., Bohlman, M. E., Liu, M. C., Fine, D. L., Mayo, J. G., and Boyd, M. R. Comparison of intrapulmonary, percutaneous intrathoracic, and subcutaneous models for the propagation of human pulmonary and nonpulmonary cancer cell lines in athymic nude mice. Cancer Res., 48: 2880-2886, 1988.
4. Manzotti, C., Audisio, R. A., and Patresi, G. Importance of orthotopic implantation for human tumors as model systems: relevance to metastasis and invasion. Clin. Exp. Metastasis, 11: 5-11, 1993.
5. Astoul, P., Wang, X., and Hoffman, R. M. "Patient-like" nude-, and SCID-mouse models of human lung and pleural cancer. Int. J. Oncol., 3: 713-718, 1993.
6. McLemore, T. L., Liu, M. C., Blacker, P. C., Gregg, M., Alley, M. C., Abbott, B. J., Shoemaker, R. H., Bolhman, M. E., Litterst, C. C., Hubbard, W. C., Brennan, R. H., McMahon, J. B., Fine, D. L., Eggleston, J. C., Mayo, J. G., and Boyd, M. R. Novel intrapulmonary model for orthotopic propagation of human lung cancers in athymic nude mice. Cancer Res., 47: 5132-5140, 1987.
7. Hamide, J. P., Qian, Z., Xu, H., Diethelm, L., Skrepnik, N., Castaneda-Zuniga, W. R., and Hunt, J. D. Percutaneous implantation of non-small-cell lung carcinoma: technique and observations. Acad. Radiol., 4: 629-633, 1997.
8. Wang, X., Fu, X., Kubota, T., and Hoffman, R. M. A new patient-like metastatic model of human small-cell lung cancer constructed orthotopically with intact tissue via thoracotomy in nude mice. Anticancer Res., 12: 1403-1406, 1992.
9. Kraus-Berthier, L., Guilbaud, N., Jan, M., Saint-Dizier, D., Rouillon, M. H., Burbridge, M., Pierré, A., and Atassi, G. Experimental antitumour activity of S 16020-2 in a panel of human tumours. Eur. J. Cancer, 33: 1881-1887, 1997.
10. Guilbaud, N., Kraus-Berthier, L., Saint-Dizier, D., Rouillon, M. H., Jan, M., Burbridge, M., Pierré, A., and Atassi, G. Antitumor activity of S 16020-2 in two orthotopic models of lung cancer. Anticancer Drugs, 8: 276-282, 1997.
11. Nagamachi, Y., Tani, M., Shimizu, K., Tsuda, H., Niitsu, Y., and Yokota, J. Orthotopic growth and metastasis of human non-small cell lung carcinoma cells injected into the pleural cavity of nude mice. Cancer Lett., 127: 203-209, 1998.
12. Le Mee, S., Pierré, A., Markovits, J., Atassi, G., Jacquemin-Sablon, A., and Saucier, J. M. S 16020-2, a new highly cytotoxic antitumor olivacine derivative: DNA interaction and DNA topoisomerase II inhibition. Mol. Pharmacol., 53: 213-220, 1998.
13. Guilbaud, N., Kraus-Berthier, L., Saint-Dizier, D., Rouillon, M. H., Jan, M., Burbridge, M., Visalli, M., Bisagni, E., Pierré, A., and Atassi, G. In vivo antitumor activity of S 16020-2, a new olivacine derivative. Cancer Chemother. Pharmacol., 38: 513-521, 1996.
14. Jasztold-Howorko, R., Landras, C., Pierré, A., Atassi, G., Guilbaud, N., Kraus-Berthier, L., Léonce, S., Rolland, Y., Prost, J. F., and Bisagni, E. Synthesis and evaluation of 9-hydroxy-5-methyl-(and 5,6-dimethyl)-6H-pyrido[4,3-b]carbazole-1-N-[(dialkylamino)alkyl]carboxamides, a newpromising series of antitumor olivacine derivatives. J. Med. Chem., 37: 2445-2452, 1994.
15. Ginsberg, R. J., Vokes, E. E., and Raben, A. Non-small cell lung cancer. In: V. T. De Vita, Jr., S. Hellman, and S. A. Rosenberg (eds.), Cancer, Principles & Practice of Oncology, Vol. 1, pp. 863-868. Philadelphia: Lippincott-Raven, 1997.
16. Naito, T., Satoh, H., Ishikawa, H., Yamashita, Y. T., Kamma, H., Takahashi, H., Ohtsuka, M., and Hasegawa, S. Pleural effusion as a significant prognostic factor in non-small cell lung cancer. Anticancer Res., 17: 4743-4746, 1997.
17. Sahn, S. A. Pleural diseases related to metastatic malignancies. Eur. Respir. J., 10: 1907-1913, 1997.
18. Edelman, M. J., and Gandara, D. R. Promising new agents in the treatment of non-small cell lung cancer. Cancer Chemother. Pharmacol., 37: 385-393, 1996.
19. Ihde, D., C. Chemotherapy of lung cancer. New England J. Med., 327: 1434-1441, 1992.
20. Bunn, P. A., Jr., and Kelly, K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin. Cancer Res., 4: 1087-1100, 1998.
21. Rajkumar, S., V., and Adjei, A., A. A review of the pharmacology and clinical activity of new chemotherapeutic agents in lung cancer. Cancer Treat. Rev., 24: 35-53, 1998.
22. Le Chevalier, T., Pujol, J. L., Douillard, J. Y., Alberola, V., Monnier, A., Riviere, A., Liane, P., Chomy, P., Cigolari, S., Besson, F., Berthaud, P., and Brisgand, D. A three-arm trial of vinorelbine (navelbine) plus cisplatin, vindesine plus cisplatin, and single-agent vinorelbine in the treatment of non-small cell lung cancer: an expanded analysis. Semin. Oncol., 21: 28-34, 1994.
23. Depierre, A., Lemarie, E., Dabouis, G., Gamier, G., Jacoulet, P., and Dalphin, J. C. A Phase II study of navelbine (vinorelbine) in the treatment of non-small-cell lung cancer. Am. J. Clin. Oncol., 14: 115-119, 1991.
24. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br. Med. J., 311: 899-909, 1995.
25. Kohler, D. R., and Golspiel, B. R. Evaluation of new drugs: paclitaxel (Taxol). Pharmacotherapy, 14: 3-34, 1994.
26. Hainsworth, J. D., Thompson, D., S., and Greco, F. A. Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer. J. Clin. Oncol., 13: 1609-1614, 1995.
27. Murphy, W. K., Fossela, F. V., Winn, R. J., Shin, D. M., Hynes, H. E., Gross, H. M., Davilla, E., Leimert, J., Dhingra, H., Raber, M. N., Krakoff, I. H., Hong, W. K. Phase II study of Taxol in patients with untreated advanced non-small-cell lung cancer. J. Natl. Cancer Inst., 85: 384-388, 1993.
28. O'Leary, J., and Muggia, F. M. Camptothecins: a review of their development and schedules of administration. Eur. J. Cancer, 34: 1500-1508, 1998.
29. Minderman, H., Cao, S., and Rustum, Y. M. Rational design of irinotecan administration based on preclinical models. Oncology, 12 (Suppl. 6): 22-30, 1998.
30. Fukuoka, M., Niitani, H., Suzuki, A., Motomiya, M., Hasegawa, K., Nishiwaki, Y., Kuriyama, T., Ariyoshi, Y., Negoro, S., Masuda, N., Nakajima, S., and Taguchi, T. A Phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J. Clin. Oncol., 10: 16-20, 1992.
31. Iyer, L., and Ratain, M., J., Clinical pharmacology of camptothecins. Cancer Chemother. Pharmacol., 42 (Suppl.). S31-S43, 1998.
32. Fidler, I. J., Wilmanns, C., Staroselsky, A., Radinsky, R., Dong, Z., and Fan, D. Modulation of tumor cell response to chemotherapy by the organ environment. Cancer Metastasis Rev., 13: 209-222, 1994.